Loading...
•
Sep 30, 2025
AbbVie Q3 2025 Earnings Report
AbbVie reported strong Q3 2025 results with revenue and adjusted EPS growth driven by Immunology and Neuroscience portfolios.
Key Takeaways
AbbVie delivered $15.776 billion in quarterly revenue and an adjusted EPS of $1.86, showing solid growth from Immunology and Neuroscience segments, partially offset by Oncology and Aesthetics softness.
Immunology revenue reached $7.885B, driven by Skyrizi and Rinvoq.
Neuroscience portfolio grew 20.2%, led by Vraylar and Botox Therapeutic.
Oncology sales declined slightly due to Imbruvica performance.
Adjusted operating margin stood at 30.9%, with a 24.5% adjusted tax rate.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
AbbVie raised its full-year 2025 adjusted EPS guidance to $10.61–$10.65, reflecting solid performance in key therapeutic areas and continued pipeline advancement.
Positive Outlook
- Raised full-year adjusted EPS guidance to $10.61–$10.65
- Strong Skyrizi and Rinvoq performance
- Neuroscience segment growing at over 20%
- Dividend increase of 5.5% announced for 2026
- Progress in advancing new therapies across pipeline
Challenges Ahead
- High GAAP tax rate of 73.7%
- Imbruvica revenue decline of nearly 15%
- Humira global revenue dropped 55%
- Aesthetics segment declined 3.7%
- Continued IPR&D and milestone expenses impacting net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...